Nevro Revenue and Competitors
Estimated Revenue & Valuation
- Nevro's estimated annual revenue is currently $393.9M per year.
- Nevro received $172.5M in venture funding in June 2016.
- Nevro's estimated revenue per employee is $348,566
- Nevro's total funding is $355.8M.
- Nevro's current valuation is $3.2B. (January 2022)
Employee Data
- Nevro has 1130 Employees.
- Nevro grew their employee count by 6% last year.
Nevro Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $42310M | 140610 | 23% | N/A | $226.6B |
#2 | $60.6M | 193 | 20% | $115.5M | N/A |
#3 | $31800M | 85784 | 3% | $367M | $146B |
#4 | $68.5M | 273 | N/A | N/A | N/A |
What Is Nevro?
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. The Nevro® Senza® SCS system received CE Mark in 2010, TGA Approval in 2011, FDA Approval in 2015, and is commercially available in Europe, Australia, and the United States.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$355.8M
Total Funding
1130
Number of Employees
$393.9M
Revenue (est)
6%
Employee Growth %
$3.2B
Valuation
N/A
Accelerator
Nevro's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sales Operations Strategy & Analytics | |
2 | Director Finance | |
3 | Senior Analyst, Rebates | |
4 | District Sales Manager | |
5 | District Manager | |
6 | District Sales Manager II, Field Sales Trainer, Field Advisory Board | |
7 | DSM III | |
8 | District Sales Manager | |
9 | Regional Sales Director | |
10 | VP, Corporate Strategy |
Nevro News
On average, analysts expect that Nevro will report full year earnings of ($2.92) per share for the current fiscal year, with EPS estimates...
Analysts expect Nevro to post earnings of ($1.11) per share for the quarter. Nevro has set its Q1 2022 guidance at EPS and its FY 2022 guidance...
Nevro Corp. NVRO is well poised for growth in the coming quarters, backed by its solid foothold in the Spinal Cord Stimulation (SCS)...
REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891, ...
REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended S ...
Other Companies in Redwood City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $241.3M | 1231 | 4% | N/A |
#2 | $149.4M | 1241 | 36% | N/A |
#3 | $233.9M | 1258 | -10% | $265.3M |
#4 | $334.5M | 1613 | -5% | $101.6M |
#5 | $519.8M | 1782 | 5% | $94.4M |
Nevro Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-07-20 | $58.0M | Undisclosed | Johnson & Johnson Development | Article |
| 2013-03-08 | $48.0M | C | Novo Ventures | Article |
| 2014-11-07 | $126.0M | Undisclosed | J.P. Morgan | Article |
| 2014-11-13 | $163.8M | Undisclosed | J.P. Morgan | Article |
| 2015-06-03 | $Undisclosed | Undisclosed | J.P. Morgan | Article |
| 2015-06-24 | $150.0M | Undisclosed | J.P. Morgan | Article |
| 2016-06-07 | $125.0M | Undisclosed | J.P. Morgan | Article |
| 2016-06-09 | $172.5M | Undisclosed | J.P. Morgan | Article |
Nevro Executives
| Name | Title |
|---|---|
| Keith Grossman | President/CEO/Chairman |
| Kathleen Determann | Associate General Counsel, Chief Compliance & Privacy Officer |
| Silvano Silva | Chief Information Security Officer |
| Niamh Pellegrini | Chief Commercial Officer |
| Geeta Kaveti | Chief Compliance Officer |
| Katie Bartkowiak | Executive Assistant to CEO and VP Corporate Development |
| David Caraway | Chief Medical Officer |
| Lori Ciano | Chief Human Resources Officer |
| Michael DeMane | Lead Director (formerly Chairman and CEO) |
| Rod MacLeod | Chief Financial Officer |
| Richard Carter | VP Finance/Corporate Controller |
| Christofer Christoforou | VP Technical Operations |
| Keith Grossman | President/CEO/Chairman |
| Julie Dewey | VP, Investor Relations and Corporate Communications |
| Jon Shear | VP, Corporate Development |
| Daniel Balkcom | VP PDN |
| Paul Mandina | Area Vice President |
| Matt Newsom | Area Vice President SE-US |
| Donald Middlebrook | Vice President, Clinical, Regulatory and Quality |
| Jon Parker | Vice President of Product Development |
| Peter Socarras | Vice President, Deputy General Counsel & Assistant Corporate Secretary |
| Patrick Schmitz | Vice President, Operations |
| Caren Carr | Area Vice President Of Sales |
| Bryan Hix | Vice President Of Commercial Operations |
| Chris Toforou | Vice President - Research and Development |
| Mark Wojtowicz | VP, US Sales |
| Becky Bilicki Chaitesipaseut | Vice President, Talent and HRBP's |
| Michael Carter | Vice President Global Sales |
| Steve Frazier | Area Vice President |
| Doug Heidrich | Vice President Sales, West |
| Neeraj Teotia | Vice President, Marketing |
| Claire Smith | Vice President, Customer Excellence |
| Katie Bartkowiak | Executive Assistant to CEO and VP Corporate Development |
| Quentin Manley | Vice President & General Manager International |
| Julie Dewey | VP, Investor Relations & Corporate Communications |
| Jon Shear | Vice President Corporate Development |
| Yougandh Chitre | Vice President, Manufacturing |